Your browser doesn't support javascript.
loading
Novel α-galactosidase A mutation in patients with severe cardiac manifestations of Fabry disease.
Duro, Giovanni; Musumeci, M Beatrice; Colomba, Paolo; Zizzo, Carmela; Albeggiani, Giuseppe; Mastromarino, Vittoria; Volpe, Massimo; Autore, Camillo.
Afiliación
  • Duro G; National Research Council, Institute of Biomedicine and Molecular Immunology "A. Monroy," 90146 Palermo, Italy.
  • Musumeci MB; Cardiology, Department of Clinical and Molecular Medicine, Sapienza University, 00189 Rome, Italy.
  • Colomba P; National Research Council, Institute of Biomedicine and Molecular Immunology "A. Monroy," 90146 Palermo, Italy.
  • Zizzo C; National Research Council, Institute of Biomedicine and Molecular Immunology "A. Monroy," 90146 Palermo, Italy.
  • Albeggiani G; National Research Council, Institute of Biomedicine and Molecular Immunology "A. Monroy," 90146 Palermo, Italy.
  • Mastromarino V; Cardiology, Department of Clinical and Molecular Medicine, Sapienza University, 00189 Rome, Italy.
  • Volpe M; Cardiology, Department of Clinical and Molecular Medicine, Sapienza University, 00189 Rome, Italy.
  • Autore C; Cardiology, Department of Clinical and Molecular Medicine, Sapienza University, 00189 Rome, Italy. Electronic address: camillo.autore@uniroma1.it.
Gene ; 535(2): 365-9, 2014 Feb 10.
Article en En | MEDLINE | ID: mdl-24140492
ABSTRACT
Fabry disease (FD) is a hereditary metabolic disorder caused by the partial or total inactivation of α-galactosidase A (α-gal A), a lysosomal hydrolase. This inactivation is responsible for the accumulation of undegraded glycosphingolipids in the lysosomes with subsequent cellular and microvascular dysfunction. Fabry is considered a rare disease, with an incidence of 140,000; however, there are good reasons to believe that it is often seen but rarely diagnosed. To date, more than 600 mutations have been identified in human GLA gene that are responsible for FD. We describe the case of a 54-year-old male patient, who presented with left ventricular hypertrophy, chronic renal failure and acroparaesthesias, which are considered to be specific features of FD. Clinical and instrumental investigations showed several cardiovascular manifestations. The molecular analysis of GLA gene revealed a novel mutation in the fifth exon, called N249K, and the enzymatic analysis showed no α-galactosidase A activity. Family screening detected the same mutation in some relatives and also the enzymatic analysis confirmed the diagnosis of FD. In conclusion, these data suggest that the N249K mutation may be associated with cardiac manifestations of FD combined with other classical features of the disease.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de Fabry / Alfa-Galactosidasa / Cardiopatías / Mutación Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Gene Año: 2014 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de Fabry / Alfa-Galactosidasa / Cardiopatías / Mutación Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Gene Año: 2014 Tipo del documento: Article País de afiliación: Italia